• The TARGET Trials interview with Dr. Andreas Baumbach

    Dr. Ron Waksman interviews Dr. Andreas Baumbach on the TARGET all-comers trial: 3 months OCT follow-up evaluating a novel cobalt chrome rapamycin DES